Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Russian Crisis - Is it a buying opportunity? -- Ignore unavailable to you. Want to Upgrade?

To: Ray Tarke who wrote (139)	9/2/1998 9:54:00 AM
From: Jeffrey L. Henken	Read Replies (2) \| Respond to of 175

Well the market has opened up a bit. We got some good news for one of the stocks we both own Ray, ABMI(OTC-BB .37), it will be interesting to see how the market receives it in this environment: American BioMed, Inc. Names LaSalle St. Securities, Inc., Its Investment Banker THE WOODLANDS, Texas, Sept. 2 /PRNewswire/ -- American BioMed, Inc. (OTC Bulletin Board: ABMI - news) today announced it has selected Chicago based LaSalle St. Securities, Inc., as its investment banker. LaSalle St. will be providing long term strategic planning and identifying alternatives for securing financing. Michael Grady, Director of Corporate Finance of LaSalle St. Securities, Inc., stated, ''During our evaluation of American BioMed, we were pleased to discover that the company has such an extensive product line, significant proprietary technologies and broad patent coverage in the rapidly growing minimally invasive surgical device market. We are looking forward to assisting the company with its capital planning and assessing numerous opportunities to maximize the value of the company's intellectual property for its shareholders.'' Steven B. Rash, President & CEO of American BioMed, said, ''The Company will utilize LaSalle's considerable expertise in helping American BioMed attain greater visibility in the financial community, attract greater institutional participation in our stock and achieve our growth objectives. We hope to draw from LaSalle's extensive experience in dealing with emerging medical device companies and their intimate knowledge of the healthcare industry.'' LaSalle St. Securities is nationally recognized as a leading regional investment banking firm with branches in 10 states across the U.S., one in Germany and over 300 registered representatives. Founded in 1974, LaSalle St. Securities offers its clients the full range of services including merger and acquisition advice, public offerings of equity and debt, as well as private placements. Their services extend to a network of independent registered representatives, banks, savings & loans, credit unions, investment advisors and futures commission merchants. American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The Company's products include 100%-silicone-based catheters through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal; the OmniCath(R), an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots and other detritus from reaching various organs of the body. The Company has over twenty-five patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion. ''Safe Harbor'' statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, the results of financing efforts, the effect of the Company's accounting policies, and other risks detailed in the Company's securities and Exchange Commission filings. SOURCE: American BioMed, Inc. biz.yahoo.com Regards, Jeff